Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Association of Toll-like receptor 2-positive monocytes with coronary artery lesions and treatment nonresponse in Kawasaki disease

  • Kang, Soo Jung (Department of Pediatrics, CHA Bundang Medical Center, CHA University School of Medicine, CHA University) ;
  • Kim, Nam Su (Department of Pediatrics, Hanyang University Hospital, Hanyang University College of Medicine)
  • Received : 2017.01.23
  • Accepted : 2017.05.23
  • Published : 2017.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Activation of Toll-like receptor 2 (TLR2) present on circulating monocytes in patients with Kawasaki disease (KD) can lead to the production of proinflammatory cytokines and interleukin-10 (IL-10). We aimed to determine the association of the frequency of circulating TLR2+/ CD14+ monocytes (FTLR2%) with the outcomes of KD, as well as to compare FTLR2% to the usefulness of sIL-10. Methods: The FTLR2% in patients with KD was measured by flow cytometry. Serum levels of IL-10 (sIL-10) were determined in 31 patients with KD before the initial treatment with intravenous immunoglobulin (IVIG) and in 21 febrile controls by using enzyme-linked immunosorbent assay. Patients were classified as having coronary artery lesions (CALs) based on the maximal internal diameters of the proximal right coronary artery and proximal left anterior descending coronary artery one month after the initial diagnosis. Results: We found that FTLR2% greater than 92.62% predicted CALs with 80% sensitivity and 68.4% specificity, whereas FTLR2% more than 94.61% predicted IVIG resistance with 66.7% sensitivity and 71.4% specificity. Moreover, sIL-10 more than 15.52 pg/mL predicted CALs and IVIG resistance with 40% and 66.7% sensitivity, respectively, and 73.7% and 76.2% specificity, respectively. Conclusion: We showed that measuring FTLR2% before the initial treatment could be useful in predicting CAL development with better sensitivity than sIL-10 and with results comparable to sIL-10 results for the prediction of IVIG resistance in patients with KD. However, further studies are necessary to validate FTLR2% as a marker of prognosis and severity of KD.

Keywords

References

  1. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44. https://doi.org/10.1016/S0140-6736(04)16814-1
  2. Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K. Nterminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. J Pediatr 2013;162:1205-9. https://doi.org/10.1016/j.jpeds.2012.11.026
  3. Sato YZ, Molkara DP, Daniels LB, Tremoulet AH, Shimizu C, Kanegaye JT, et al. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol 2013;164:58-63. https://doi.org/10.1016/j.ijcard.2011.06.065
  4. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. https://doi.org/10.1542/peds.2004-2182
  5. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117-21. https://doi.org/10.1016/j.jpeds.2007.12.021
  6. Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 2003;24:122-6. https://doi.org/10.1007/s00246-002-0063-1
  7. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113: 2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  8. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
  9. Koga M, Ishihara T, Takahashi M, Umezawa Y, Furukawa S. Activation of peripheral blood monocytes and macrophages in Kawasaki disease: ultrastructural and immunocytochemical investigation. Pathol Int 1998;48:512-7. https://doi.org/10.1111/j.1440-1827.1998.tb03942.x
  10. Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med 1988;319:1670-1. https://doi.org/10.1056/NEJM198812223192515
  11. Ueno Y, Takano N, Kanegane H, Yokoi T, Yachie A, Miyawaki T, et al. The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illnesses. Clin Exp Immunol 1989;76:337-42.
  12. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-84. https://doi.org/10.1038/ni.1863
  13. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 1990;10:1498-506. https://doi.org/10.1128/MCB.10.4.1498
  14. Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993;13:6231-40. https://doi.org/10.1128/MCB.13.10.6231
  15. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990;10:2327-34. https://doi.org/10.1128/MCB.10.5.2327
  16. Rosenkranz ME, Schulte DJ, Agle LM, Wong MH, Zhang W, Ivashkiv L, et al. TLR2 and MyD88 contribute to Lactobacillus casei extractinduced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation 2005;112:2966-73. https://doi.org/10.1161/CIRCULATIONAHA.105.537530
  17. Schulte DJ, Yilmaz A, Shimada K, Fishbein MC, Lowe EL, Chen S, et al. Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease. J Immunol 2009;183:5311-8. https://doi.org/10.4049/jimmunol.0901395
  18. Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, et al. Interleukin-$1{\beta}$ is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 2012;125:1542-50. https://doi.org/10.1161/CIRCULATIONAHA.111.072769
  19. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765. https://doi.org/10.1146/annurev.immunol.19.1.683
  20. Weng KP, Hsieh KS, Hwang YT, Huang SH, Lai TJ, Yuh YS, et al. IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease. Circ J 2010;74:983-9. https://doi.org/10.1253/circj.CJ-09-0801
  21. Guo MM, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy 2015;70:310-8. https://doi.org/10.1111/all.12558
  22. McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation 2007;116:174-9. https://doi.org/10.1161/CIRCULATIONAHA.107.690875
  23. Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K, et al. Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 2009;168:1315-21. https://doi.org/10.1007/s00431-009-0925-0
  24. Lin IC, Kuo HC, Lin YJ, Wang FS, Wang L, Huang SC, et al. Augmented TLR2 expression on monocytes in both human Kawasaki disease and a mouse model of coronary arteritis. PLoS One 2012;7:e38635. https://doi.org/10.1371/journal.pone.0038635
  25. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301. https://doi.org/10.4049/jimmunol.176.10.6294
  26. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005;111: 2654-61. https://doi.org/10.1161/CIRCULATIONAHA.104.498865
  27. Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 2013;65:805-14. https://doi.org/10.1002/art.37815
  28. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, et al. NF-kappaB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001;99:373-7. https://doi.org/10.1006/clim.2001.5026
  29. Moran AM, Newburger JW, Sanders SP, Parness IA, Spevak PJ, Burns JC, et al. Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin. Am Heart J 2000;139(2 Pt 1):217-23. https://doi.org/10.1016/S0002-8703(00)90229-1
  30. Yu JJ, Choi HS, Kim YB, Son JS, Kim YH, Ko JK, et al. Analyses of left ventricular myocardial deformation by speckle-tracking imaging during the acute phase of Kawasaki disease. Pediatr Cardiol 2010;31:807-12. https://doi.org/10.1007/s00246-010-9708-7

Cited by

  1. Epigenetic Regulation of Macrophage Marker Expression Profiles in Kawasaki Disease vol.8, pp.None, 2017, https://doi.org/10.3389/fped.2020.00129
  2. The Expression of Glycoprotein Genes in the Inflammatory Process of Kawasaki Disease vol.8, pp.None, 2017, https://doi.org/10.3389/fped.2020.592122